Vyndaqel Market to Witness Significant Growth of USD $4.19 Billion with 17.1% CAGR by 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Will Be the Forecast Market Size of the Global Vyndaqel Market by 2030?
The vyndaqel market size has grown rapidly in recent years. It will grow from $1.9 billion in 2025 to $2.23 billion in 2026 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to approval of tafamidis, lack of effective attr-cm treatments, improved cardiac imaging diagnostics, growth of rare disease programs, increasing cardiology referrals.

The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to aging population growth, rising awareness of amyloid cardiomyopathy, expansion of specialty cardiology centers, increased genetic testing adoption, growing reimbursement support. Major trends in the forecast period include increasing adoption of transthyretin stabilizers, rising diagnosis of attr cardiomyopathy, expansion of oral therapies for rare cardiac diseases, growing focus on disease-modifying cardiac drugs, increased use of long-term amyloidosis treatment.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

Which Key Growth Contributors Will Drive the Vyndaqel Market in the Next Decade?
The growing adoption of precision medicine is expected to propel the growth of the Vyndaqel market going forward. Precision medicine involves tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors, improving treatment effectiveness and outcomes. The adoption of precision medicine is increasing as more patients and healthcare providers prefer personalized therapies that ensure targeted treatment and better management of chronic diseases. Vyndaqel enhances precision medicine by offering targeted therapy for transthyretin amyloidosis (ATTR), ensuring patients who will benefit most receive the treatment. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of precision medicine is driving the growth of the vyndaqel market.

What Are the Emerging Segments in the Vyndaqel Market?
The vyndaqel market covered in this report is segmented –

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)
2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use
2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

What Are the Emerging Market Trends That Companies Should Monitor in Vyndaqel Market?
Major companies operating in the vyndaqel market is focusing on facility expansions to produce active pharmaceutical ingredients, such as transthyretin stabilizing therapeutic to enhance cardiovascular outcomes and reduce hospitalization in patients with ATTR-CM. Transthyretin stabilizing therapeutic refers to a pharmacological agent designed to bind and stabilize transthyretin (TTR) tetramers, preventing their dissociation into misfolded monomers that aggregate and form amyloid deposits. For instance, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, launched Attruby (acoramidis), a near-complete (≥90%) transthyretin (TTR) stabilizer designed to address key challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) binds and stabilizes TTR tetramers, preventing their dissociation into misfolded monomers that form amyloid deposits in cardiac tissue. The therapy offers significant cardiovascular benefits, including reduction in cardiovascular death and cardiovascular-related hospitalizations, while preserving TTR’s native physiological functions making it an effective treatment for improving patient outcomes and disease management in ATTR-CM.

Who Are the Top Companies Contributing to the Vyndaqel Market Expansion?
Major companies operating in the vyndaqel market are Pfizer Inc.

Get the full vyndaqel market report here:
https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

Which Region Is Projected to Account for the Largest Share of the Vyndaqel Market?
North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn